摘要
目的进行吉非替尼治疗非小细胞肺癌（NSCLC）优势患者血清蛋白质指纹验证。方法选取服用吉非替尼治疗1个月以上并已知疗效的NSCLC患者27例，按实体瘤疗效评价标准分为完全缓解＋部分缓解（CR＋PR）、稳定（SD）、进展（PD）三种疗效患者。所有患者在服用吉非替尼前均行表面增强激光解析电离（SELDI）检查，以M／Z：8693±50H^＋为筛选依据，根据其丰度分成优势患者组（丰度≤10％）10例，劣势患者组（丰度≥30％）7例，疑似组A（丰度：11％～15％）5例，疑似组B（丰度：16％～29％）5例。分析四组中，每组CR＋PR、SD及PD患者的比例。结果优势患者组中，CR＋PR患者占9／10，SD患者占1／10，PD患者为0；劣势患者组中，CR＋PR患者占1／7，SD患者占1／7，PD患者占5／7；疑似组A中，CR＋PR患者占3／5，SD、PD患者各占1／5；疑似组B中，CR＋PR患者占3／5，SD、PD患者各占1／5。结论经SELDI检测，蛋白质指纹图谱符合M／Z：8693±50H^＋丰度≤10％可以作为吉非替尼治疗NSCLC优势患者的筛选指标。
Objective Verification of the serum proteomic fingerprints of NSCLC （non-small cell lung cancer） patients related to their advantage in Gefitinib therapy. Methods 27 NSCLC patients who have been treated with Gefitinib for more than 1 month and attained certain efficacy were taken for examination. They were divided into 3 groups, CR＋PR, SD and PD, according to the evaluation criteria of solid tumor curative efficacy. All patients received SELDI （SELDI-TOF-MS surface-enhanced laser desorption/ionization time-of-flight mass spectrometry technique ） inspection before treatment with Gefitinib. The shifting procedure was based on the abundance of the fingerprint ：＂M/Z 8693 50H^＋＂. According to the abundance of this fingerprint founded, the patients were divided into 4 populations： 1. The advantage population （ 10 patients, abundance 10 %）; 2. The disadvantage population （ 7 patients, abundance ≥ 30 %）; 3. Suspected population A （ 5 patients, abundance 11%-15 %） ; 4. Suspected population B （5 patients, abundance 16- 29%）. The ratio of patients in each of the 3 groups （ CR ＋ PR, SD and PD ） into each of the above 4 populations were analyzed. Results It showed that： 1. In the advantage population, the ratio dispersed from CR ＋ PR group is 9/10, those from SD group is 1/10 and from PD is 0. 2. In the disadvantage population, the ratio dispersed from CR ＋ PR group is 1/7, those from SD group is 1/7 and from PD is 5/7. In the suspected A group, the ratio from CR ＋ PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. 4. In the suspected B group, the ratio from CR ＋ PR group is 3/5, those from SD group is 1/5 and from PD is 1/5. Conclusion This fingerprint ＂M/Z 8693 50H^＋＂ with abundance 10% after SELDI inspection is the index choosing advantage patients suitable to receive Gefitinib therapy.
出处
《肿瘤研究与临床》
CAS
2009年第6期393-395,共3页
Cancer Research and Clinic
